A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Symptomatic Ulcerative Colitis Patients With Moderate to Severe Disease Activity
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2017
At a glance
- Drugs TOP 1288 (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors TopiVert
- 06 Jul 2017 Status changed from recruiting to completed.
- 28 Feb 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jun 2017.
- 06 Jan 2017 Planned number of patients changed from 60 to 80.